Essential Medicines at the National Level: The Global Asthma Network’s Essential Asthma Medicines Survey 2014

• Main Authors: Karen Bissell, Philippa Ellwood, Eamon Ellwood, Chen-Yuan Chiang, Guy B. Marks, Asma El Sony, Innes Asher, Nils Billo, Christophe Perrin, the Global Asthma Network Study Group
• Format: Article
• Language: English
• Published: MDPI AG 2019-02-01
• Series: International Journal of Environmental Research and Public Health
• Subjects: essential medicines; access; noncommunicable diseases; asthma; inhaled corticosteroids; bronchodilators; national reimbursement list
• Online Access: https://www.mdpi.com/1660-4601/16/4/605

Patients with asthma need uninterrupted supplies of affordable, quality-assured essential medicines. However, access in many low- and middle-income countries (LMICs) is limited. The World Health Organization (WHO) Non-Communicable Disease (NCD) Global Action Plan 2013–2020 sets an 80% target for essential NCD medicines’ availability. Poor access is partly due to medicines not being included on the national Essential Medicines Lists (EML) and/or National Reimbursement Lists (NRL) which guide the provision of free/subsidised medicines. We aimed to determine how many countries have essential asthma medicines on their EML and NRL, which essential asthma medicines, and whether surveys might monitor progress. A cross-sectional survey in 2013–2015 of Global Asthma Network principal investigators generated 111/120 (93%) responses—41 high-income countries and territories (HICs); 70 LMICs. Patients in HICs with NRL are best served (91% HICs included ICS (inhaled corticosteroids) and salbutamol). Patients in the 24 (34%) LMICs with no NRL and the 14 (30%) LMICs with an NRL, however no ICS are likely to have very poor access to affordable, quality-assured ICS. Many LMICs do not have essential asthma medicines on their EML or NRL. Technical guidance and advocacy for policy change is required. Improving access to these medicines will improve the health system’s capacity to address NCDs.